JOHN-MICHAEL CYCZ: Open Payments
NPI 1326448036 · SPRINGFIELD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$697 in 31 payments from 12 companies in 2025. Trend: 2023 $934 · 2024 $899 · 2025 $697
Food & beverage: $697
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $125 |
| PFIZER INC. | 5 | $115 |
| SCPHARMACEUTICALS INC. | 3 | $64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $60 |
| ABIOMED | 2 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $55 |
| Amgen Inc. | 3 | $52 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $42 |
| BridgeBio Pharma, Inc. | 2 | $39 |
Products named: LEQVIO, VYNDAQEL, FUROSCIX, JARDIANCE, ONPATTRO, Repatha, Kerendia, Attruby.
Industry payments across MA — which companies pay providers there.
